Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”), a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has appointed a leading orthopedic physician scientist recognized for his work in orthobiologics and regenerative medicine, Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer.
Dr. Law will lead the Company’s efforts to develop and advance an integrated platform of exosome-based therapies, topical plant-derived formulations, injectable hydrogel-exosome candidates, and exosomal biomarker panels designed to address a broad spectrum of patient needs and therapeutic goals.
Dr. Law is a South Florida–based orthopedic medicine physician scientist specializing in hip and knee osteoarthritis, with a focus on orthobiologics and regenerative medicine. He serves as Director of Clinical Research at HSS Florida, where he leads studies on orthobiologic therapies, such as microfragmented adipose tissue, aiming to enhance treatment options for osteoarthritis. Dr. Law has been featured in Medscape, where he discussed the current landscape and challenges of orthobiologic treatments.
Figure 1 – Human Continuum Inc. Appoints Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer.
“Health and longevity have always been essential priorities, and it’s clear that more people today are taking a proactive interest in both,” said Dr. Sean Law, MD, MBA, Chief Executive Officer and Board Member of Human Continuum. “Exosome-based therapies represent an important next step in advancing wellness and recovery, regardless of age. Exosomes, like those being developed by Human Continuum, have shown meaningful potential in easing chronic symptoms and improving outcomes for a range of common injuries and conditions. The next challenge lies in their accessibility, and we are aiming to meet this challenge head on, making these treatments available, affordable, and scalable beyond the research setting to the benefit of all.”
Dr. Law's research spans the integration of robotic and sensor technologies in orthopedic care to orthobiologics in regenerative medicine. His work has been published in numerous peer-reviewed journals and presented at both national and international conferences.
Musculoskeletal diseases affect more than 60 million adults in the United States, including arthritis, osteoporosis, back pain, and other degenerative or inflammatory conditions. Our platelet-derived exosome infusion harnesses the regenerative signaling of stem cells, without the cells themselves, offering a minimally invasive, scalable, and standardized approach for systemic rejuvenation and inflammation control.
About Human Continuum Inc.
Human Continuum Inc. is developing a platform of exosome-based therapeutics and diagnostics spanning longevity, orthopedics, aesthetics, and dermatology. Our lead program is an investigational IV infusion of standardized, cell-free, platelet-derived exosomes designed to deliver regenerative signals that may help modulate systemic inflammation and support cellular health.
Beyond IV infusion, we are advancing:
• Injectable hydrogel–exosome candidates for musculoskeletal conditions (e.g., osteoarthritis, tendon and ligament injuries), engineered for localized, sustained delivery.
• Topical plant-derived exosome formulations for skin appearance and barrier support, with scalable isolation and QC built for consumer and clinic settings.
• Point-of-care diagnostics for rapid joint-infection detection using synovial-fluid exosomal biomarkers.
• Exosomal biomarker panels to aid early diagnosis and longitudinal monitoring of orthopedic disease.
For more corporate information please visit: humancontinuum.com
For further Human Continuum information, please contact:
Email: Info@hcontiuum.com
Business Tel: 877-484-8626
PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:
Human Continuum LINKEDIN
Human Continuum X
Forward Looking Statements
This news release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as "expects", "anticipates", "intends", "plans", "believes", "will", "should", "could", "would" or "may" and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control. For Human Continuum Inc., particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following which are, and will be, exacerbated by any worsening of global business and economic environment: (i) risks related to the development of new or advanced technology, including difficulties with design and testing, cost overruns, development of competitive technology, loss of key individuals and uncertainty of success of patent filing, (ii) our ability to obtain contracts and funding to be able to continue operations and (iii) risks related to uncertainty regarding our ability to commercially deploy a competitive platform of exosome-based therapeutics and diagnostics spanning longevity, orthopedics, aesthetics, and dermatology, (iv) risks related to the impact of government regulation and policies including by the FDA; and other risks and uncertainties discussed in this and our other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
Attachment
Figure 1
Human Continuum Inc. Appoints Dr. Tsun “Sean” Law, MD, MBA as its Chief Executive Officer.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
